Walid Fawaz, MD
Child & Adolescent Psychiatry · Hopewell, VANPI 1477714111
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations.
Across 46 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$113
- E.r. Squibb & Sons, L.L.C.$91
- Indivior Inc.$88
- Ironshore Pharmaceuticals Inc.$82
- Sunovion Pharmaceuticals Inc.$77
- Otsuka America Pharmaceutical, Inc.$74
- plus $348 from 13 others
What the payments were for
- Food & beverage$873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 6 | $113 |
| E.r. Squibb & Sons, L.L.C. | 4 | $91 |
| Indivior Inc. | 3 | $88 |
| Ironshore Pharmaceuticals Inc. | 4 | $82 |
| Sunovion Pharmaceuticals Inc. | 5 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Lundbeck LLC | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| TMS Neurohealth Centers Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
How this compares
$873 in reported general payments places this provider in the 70th percentile of 115 child & adolescent psychiatry providers in Virginia.
See all child & adolescent psychiatry providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 16 | $2,179 |
| Paliperidone ErPaliperidone | 24 | $1,732 |
| Atomoxetine Hcl | 12 | $1,157 |
| Buspirone Hcl | 23 | $693 |
| Trifluoperazine Hcl | 12 | $390 |
| Sertraline Hcl | 39 | $267 |
| Bupropion XlBupropion Hcl | 16 | $246 |
| Duloxetine Hcl | 14 | $230 |
| Olanzapine | 14 | $150 |
| Quetiapine Fumarate | 12 | $146 |
| Hydroxyzine Pamoate | 17 | $116 |
| Prazosin Hcl | 18 | $101 |
| Trazodone Hcl | 29 | $96 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Hopewell
- Rakesh ShahHopewell$7K
- Charles HallRichmond$10K
- Chandramouleswar AmaraPetersburg$10K
- David GouldRichmond$9K
- Vikas MangewalaFairfax$7K
- Maria Carmen Rita Gonzales VigilarAshburn$6K
- Stacy PaggiFairfax$6K
- Craig SwaineyRichmond$5K
- Hemalatha MukharaManassas$4K
- Temitope OyegbileMc Lean$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.